Newron Pharmaceuticals Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: Bresso Lombardia Italy (1998)

Organization Overview

First Clinical Trial
2004
NCT00736151
First Marketed Drug
2017
safinamide (xadago)
First NDA Approval
2017
safinamide (xadago)
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Newron | Newron Pharmaceuticals | Newron Pharmaceuticals SPA | Newron Sweden AB